CB2 receptor activation reduced fentanyl-induced respiratory depression in mice

The CB2 cannabinoid receptor agonist LY2828360 attenuated fentanyl-induced respiratory depression in normal mice but not in CB2 knockout mice, suggesting a CB2-mediated protective effect.

Zavala, Carmen A et al.·Cannabis and cannabinoid research·2021·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-03633Animal StudyPreliminary Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Co-administration of LY2828360 (3 mg/kg) with fentanyl (0.2 mg/kg) attenuated respiratory depression in wild-type mice but not CB2 knockout mice, confirming the effect was CB2-mediated. LY2828360 alone had no effect on respiratory parameters in either genotype.

Key Numbers

Fentanyl doses: 0.1 and 0.2 mg/kg. LY2828360 dose: 3 mg/kg. Higher fentanyl dose produced greater respiratory suppression. CB2 agonist attenuated depression in WT but not CB2KO mice.

How They Did This

Whole-body plethysmography in wild-type and CB2 knockout mice. Measured minute ventilation, respiratory frequency, and tidal volume after fentanyl alone vs. fentanyl + LY2828360 co-administration.

Why This Research Matters

Opioid-induced respiratory depression is the primary cause of overdose deaths. A cannabinoid compound that reduces this risk without itself affecting breathing could be a breakthrough in harm reduction.

The Bigger Picture

With fentanyl responsible for more overdose deaths than any other opioid, finding compounds that specifically counteract its respiratory depression while potentially enhancing pain relief represents a promising harm reduction strategy.

What This Study Doesn't Tell Us

Animal study in mice. Unknown whether CB2 agonists would have the same effect in humans. Single dose combination tested. Long-term effects unknown.

Questions This Raises

  • ?Would CB2 agonists maintain opioid pain relief while reducing respiratory depression in humans?
  • ?Could this approach be developed into a co-formulation with opioids?

Trust & Context

Key Stat:
CB2 agonist attenuated fentanyl respiratory depression in wild-type but not knockout mice
Evidence Grade:
Well-designed animal study with knockout confirmation of mechanism, but requires human translation.
Study Age:
Published in 2021.
Original Title:
Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression.
Published In:
Cannabis and cannabinoid research, 6(5), 389-400 (2021)
Database ID:
RTHC-03633

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can cannabinoids prevent opioid overdose?

In mice, a CB2 cannabinoid receptor agonist reduced fentanyl-induced respiratory depression, the primary cause of overdose death. The compound itself did not affect breathing.

How was the CB2 mechanism confirmed?

The protective effect occurred in normal mice but disappeared in mice genetically lacking CB2 receptors, confirming the effect was specifically mediated through CB2.

Read More on RethinkTHC

Cite This Study

RTHC-03633·https://rethinkthc.com/research/RTHC-03633

APA

Zavala, Carmen A; Thomaz, Ana C; Iyer, Vishakh; Mackie, Ken; Hohmann, Andrea G. (2021). Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression.. Cannabis and cannabinoid research, 6(5), 389-400. https://doi.org/10.1089/can.2020.0059

MLA

Zavala, Carmen A, et al. "Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression.." Cannabis and cannabinoid research, 2021. https://doi.org/10.1089/can.2020.0059

RethinkTHC

RethinkTHC Research Database. "Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Indu..." RTHC-03633. Retrieved from https://rethinkthc.com/research/zavala-2021-cannabinoid-cb2-receptor-activation

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.